|1.||Yang, Jinghua: 2 articles (04/2013 - 01/2013)|
|2.||Xiao, Sha: 2 articles (04/2013 - 01/2013)|
|3.||Wu, Shengwen: 2 articles (04/2013 - 01/2013)|
|4.||Liu, Yanhua: 2 articles (04/2013 - 01/2013)|
|5.||Jin, Cuihong: 2 articles (04/2013 - 01/2013)|
|6.||Yu, Tao: 2 articles (04/2013 - 01/2013)|
|7.||Liu, Qiufang: 2 articles (04/2013 - 01/2013)|
|8.||Lu, Xiaobo: 2 articles (04/2013 - 01/2013)|
|9.||Shen, Shengwen: 2 articles (05/2009 - 02/2009)|
|10.||Le, X Chris: 2 articles (05/2009 - 02/2009)|
|1.||Lung Neoplasms (Lung Cancer)
02/01/2012 - "GSTM1 null genotype individuals with BPDE-DNA level higher than 5 adducts/10(8) nucleotide have increased risk of lung cancer (OR= 1.988, 95%CI: 1.011-3.912). "
02/01/2012 - "[Effects of CYP1A1 and GSTM1 gene polymorphisms and BPDE-DNA adducts on lung cancer]."
05/01/2009 - "High levels of benzo(a)pyrene diol epoxide (BPDE)-DNA adducts in white blood cells have been indicated as a risk factor for lung cancer. "
12/01/2002 - "Benzo[a]pyrene diol epoxide (BPDE)-DNA adducts are involved in the induction of p53 mutations and probably in the causation of human lung cancer associated with cigarette smoking. "
01/01/2000 - "Higher levels of BPDE-DNA adducts in individuals with the combined CYP1A1(1/*2 or *2A/*2A)-GSTM1*0/*0 genotype suggest that these genotype combinations are at increased risk for contracting lung cancer when exposed to PAH."
|2.||Xeroderma Pigmentosum (Kaposi's Disease)
08/01/2008 - "Excision repair cross-complementing complementation group 1 (ERCC1) and excision repair cross-complementing complementation group 2/xeroderma pigmentosum D (ERCC2/XPD) participate in the nucleotide excision repair (NER) pathway that removes BPDE-DNA adducts; however, few studies have provided population-based evidence for this association. "
02/01/2009 - "Use of a nucleotide excision repair (NER)-deficient Xeroderma pigmentosum complementation group A cell line (GM04312C) allowed us to dissect DNA damage induction from DNA repair and to examine the effects of arsenic on the formation of BPDE-DNA adducts only. "
01/01/2013 - "ERCC2/XPD Arg156Arg rs238406 polymorphisms may be associated with DNA repair capacity in excising BPDE-DNA adduct and A allele may increase the risks of cancer susceptibility."
08/15/1996 - "We found that the peripheral lymphocytes of cancer patients tended to accumulate higher levels of BPDE-DNA adducts than controls did (mean +/- SE of relative adduct labeling x 10(7) value; 59.6 +/- 12.0 versus 39.4 +/- 6.1 for cases and controls, respectively; P = 0.09). "
04/01/2013 - "Our findings suggests that ERCC1 C8092A (rs3213986) is associated with a diminished capacity of repairing BPDE-DNA adducts and may be used as a valid biomarker to predict an individual's risk to develop cancer upon exposure to environmental carcinogens."
06/01/1996 - "TPA, a well-known tumor promoter, decreased the response of nuclear p53 immunoreactivity to benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE)-DNA adducts in C57BL/6 mouse skin in vivo. "
09/05/1992 - "No increase in (-)-anti-BPDE-DNA was observed when the non-tumor-promoting phorbol ester 4-O-methyl-TPA was substituted for TPA. "
09/07/2013 - "The proposed plastic antibody-based FIPCIA method can detect traces of BPDE-DNA adducts as low as 18 pM in human lung carcinoma A549 cells. "
11/01/2001 - "A competitive immunoassay using the fluorescent probe and CE/LIF is demonstrated for the analysis of BPDE-DNA adducts in A549 human lung carcinoma cells incubated with 2.5, 5, and 10 microM BPDE for 2 h. "
08/10/2009 - "Benzo(a)pyrene (BP) forms benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE)-DNA adducts in human breast adenocarcinoma MCF-7 cells, leading to p53 protein induction and phosphorylation. "
12/01/2002 - "Human peripheral blood cell (buffy coat) DNA samples (n = 43) obtained from 25 individuals who were either colorectal adenocarcinoma patients or controls were assayed by BPDE-DNA CIA. "
|2.||DNA (Deoxyribonucleic Acid)
|8.||Cytochrome P-450 CYP1A1 (CYP1A1)